The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet's disease

References

• Yazıcı H. Behçet’s syndrome in the 2000s: “Where is the wisdom we have lost in knowledge?”. Clin Exp Rheumatol. 2016;34:S23–S25.
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Nasothimiou EG, Sfikakis PP, et al. Non-invasive vascular biomarkers in patients with Behçet's disease: review of the data and future perspectives. Clin Exp Rheumatol. 2017;35:100–107.
   PubMed Web of Science ®Google Scholar
• de Jesus H, Rosa M, Queiroz MV. Vascular involvement in Behcet’s disease. An analysis of twelve cases. Clin Rheumatol. 1997;16:220–221.
   PubMed Web of Science ®Google Scholar
• Düzgün N, Ateş A, Aydintuğ OT, et al. Characteristics of vascular involvement in Behçet's disease. Scand J Rheumatol. 2006;35:65–68.
   PubMed Web of Science ®Google Scholar
• Tascilar K, Melikoglu M, Ugurlu S, et al. Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53:2018–2022.
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Karadeniz A, Ylmaz S, et al. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94:e494.
   PubMed Web of Science ®Google Scholar
• Yalçındağ A, Gedik-Oğuz Y, Yalçındağ FN. The relationship between serum levels of angiogenin, bFGF, VEGF, and ocular involvement in patients with Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2013;251:1807–1812.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Ayed K, Hamza M, et al. VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement. J Neuroimmunol. 2009;213:148–153.
   PubMed Web of Science ®Google Scholar
• Kamoun M, Houman MH, Hamzaoui A, et al. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. Tissue Antigens. 2008;72:581–587.
   PubMed Web of Science ®Google Scholar
• Oztürk MA, Unverdi S, Oktar SO, et al. Vascular endothelial growth factor and carotid intima-media thickness in patients with Behçet's disease. Clin Rheumatol. 2008;27:961–966.
   PubMed Web of Science ®Google Scholar
• Kosugi T, Nakayama T, Li Q, et al. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Am J Physiol Renal Physiol. 2010;298:F609–F616.
   PubMed Web of Science ®Google Scholar
• Hornig C, Barleon B, Ahmad S, et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000;80:443–454.
   PubMed Web of Science ®Google Scholar
• Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci. 1998;95:8795–8800.
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88:2348–2351.
   PubMed Web of Science ®Google Scholar
• Shapiro NI, Yano K, Okada H, et al. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock. 2008;29:452–457.
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Chikaraishi Y, Izuta H, et al. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology. 2008;115:1916–1922.
   PubMed Web of Science ®Google Scholar
• International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Fresko I, Direskeneli H, et al. Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. Rheumatology (Oxford)). 1999;38:734–736.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612. Erratum in: Ann Intern Med. 2011;155:408.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50:297–350.
   PubMed Web of Science ®Google Scholar
• Cakmak OS, Seyahi E, Kantarci F, et al. Venous severity assessment in Behçet's syndrome. Clin Exp Rheumatol. 2010;28:S-139.
   Web of Science ®Google Scholar
• Güngen AC, Çoban H, Aydemir Y, et al. Consider Behcet's Disease in young patients with deep vein thrombosis. Respir Med Case Rep. 2016;18:41–44.
   PubMed Web of Science ®Google Scholar
• Özoran K, Düzgün H, Gürler A, et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet’s disease. Scand J Rheumatol. 1995;24:376–382.
   PubMed Web of Science ®Google Scholar
• Haznedaroğlu IC, Özdemir O, Özcebe O, et al. Circulating thrombomodulin as a clue of endothelial damage in Behçet's disease. Thromb Haemost. 1996;75:974–975.
   PubMed Web of Science ®Google Scholar
• Saglam K, Yilmaz MI, Saglam A, et al. Levels of circulating intercellular adhesion molecule-1 in patients with Behçet's disease. Rheumatol Int. 2002;21:146–148.
   PubMed Web of Science ®Google Scholar
• Cekmen M, Evereklioglu C, Er IHS, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s Syndrome. Int J Dermatol. 2003;42:870–875.
   PubMed Web of Science ®Google Scholar
• Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19:998–1003.
   PubMed Web of Science ®Google Scholar
• Paroli MP, Teodori C, D'Alessandro M, et al. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol. 2007;17:938–942.
   PubMed Web of Science ®Google Scholar
• Scaria A, Pechan P, Lukason M, et al. Inhibition of retinal neovascularization by intraocular gene delivery of soluble VEGF receptors. Mol Ther. 2004;9:198.
   PubMed Web of Science ®Google Scholar
• Shaker O, Ay El-Deen MA, El Hadidi H, et al. The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease. Br J Dermatol. 2007;156:32–37.
   PubMed Web of Science ®Google Scholar
• Bozoglu E, Dinc A, Erdem H, et al. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patientswith venous thrombosis. Clin Exp Rheumatol. 2005;23:S42–S48.
   PubMed Web of Science ®Google Scholar
• Erdem F, Gündoğdu M, Kiki I, et al. Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behcet’s disease. Rheumatol Int. 2005;25:599–603.
   PubMed Web of Science ®Google Scholar
• Arisato T, Hashiguchi T, Sarker KP, et al. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J Thromb Haemost. 2003;1:2589–2593.
   PubMed Web of Science ®Google Scholar
• Maloney JP, Silliman CC, Ambruso DR, et al. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 1998;275:H1054–H1061.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276:7614–7620.
   PubMed Web of Science ®Google Scholar
• Falk RT, Staff AC, Bradwin G, et al. A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control. 2016;27:1009–1017.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:167–178.
   PubMed Web of Science ®Google Scholar
• Javanmard SH, Hasanpour Z, Abbaspoor Z, et al. Aqueous concentrations of VEGF and soluble VEGF receptor-1 in diabetic retinopathy patients. J Res Med Sci. 2012;17:1124–1127.
   PubMed Web of Science ®Google Scholar
• Kim NH, Oh JH, Seo JA, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 2005;67:167–177.
   PubMed Web of Science ®Google Scholar
• Di Marco GS, Reuter S, Hillebrand U, et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol. 2009;20:2235–2245.
   PubMed Web of Science ®Google Scholar
• Yuan J, Guo Q, Qureshi AR, et al. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. Nephrol Dial Transplant. 2013;28:2356–2363.
   PubMed Web of Science ®Google Scholar
• Blann AD, Belgore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci. 2002;102:187–194.
   PubMed Web of Science ®Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–350.
   PubMed Web of Science ®Google Scholar
• Zeng J, Yang L, Huang F, et al. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2016;78:801–808.
   PubMed Web of Science ®Google Scholar